



The potential value of *Clostridium difficile* vaccine: An economic computer simulation model

Bruce Y. Lee^{a,b,c,*}, Michael J. Popovich^{a,b,c}, Ye Tian^{a,b,c}, Rachel R. Bailey^{a,b,c}, Paul J. Ufberg^{a,b,c}, Ann E. Wirlinga^{a,b,c}, Robert R. Muder^d

^a Applied Modeling, Public Health Computational and Operations Research Group (PHICOR), University of Pittsburgh, Pittsburgh, PA, United States

^b Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, United States

^c Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, United States

^d Division of Infectious Diseases, VA Pittsburgh Health System, University of Pittsburgh, Pittsburgh, PA, United States

ARTICLE INFO

Article history:

Received 18 October 2009

Received in revised form 6 May 2010

Accepted 26 May 2010

Available online 10 June 2010

Keywords:

Clostridium difficile

Vaccine

Economics

Computer simulation

ABSTRACT

Efforts are currently underway to develop a vaccine against *Clostridium difficile* infection (CDI). We developed two decision analytic Monte Carlo computer simulation models: (1) an Initial Prevention Model depicting the decision whether to administer *C. difficile* vaccine to patients at-risk for CDI and (2) a Recurrence Prevention Model depicting the decision whether to administer *C. difficile* vaccine to prevent CDI recurrence. Our results suggest that a *C. difficile* vaccine could be cost-effective over a wide range of *C. difficile* risk, vaccine costs, and vaccine efficacies especially, when being used post-CDI treatment to prevent recurrent disease.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

Efforts are currently underway to develop a vaccine against *Clostridium difficile* infection (CDI), a major and potentially growing cause of substantial morbidity, costs, and mortality throughout the developed world [1–9]. Although numerous interventions have been implemented to control the spread of *Clostridium difficile* (*C. difficile*) in hospitals, the bacterial pathogen remains established in many locations and continues to spread to others. CDI can result in longer hospital length-of-stay, necessitate antibiotic use that may lead to more antibiotic-resistant bacteria, and even require surgical procedures. A significant percentage of treated patients may experience relapse of disease, in some cases multiple relapses [10]. Moreover, the recent emergence of more virulent strains may make combating the nosocomial pathogen even more difficult [11].

Candidate *C. difficile* vaccines currently are in pre-clinical and early clinical development and show promise as options for both preventing and treating CDI. A potential vaccine containing *C. difficile* toxoids A and B has been shown to induce immune response in healthy adults [12]. Antibody levels measured from study partici-

pants exceeded the level previously shown to be associated with CDI prevention [9]. There is also evidence that such a vaccine could effectively treat recurrent infections, particularly those that other methods have failed to remedy [8].

Constructing economic models early in a vaccine's development can help identify appropriate target populations, establish vaccine efficacy targets, assist in pricing and reimbursement decisions, and help determine the investment that should be made into developing the vaccine when substantial changes are still possible. A number of vaccines have faced challenges when economic modeling occurred too late in the vaccine timeline to make necessary changes [13]. To answer such questions regarding *C. difficile* vaccine, we constructed computer models to simulate the decision of whether to administer *C. difficile* vaccine to patients. One model simulated the choice of whether to perform universal vaccination on at-risk patients. A second model simulated the option of vaccinating those currently with CDI and undergoing antibiotic treatment to prevent recurrence. Sensitivity analyses explored how the economic value of the vaccine varied with CDI risk, vaccine cost, and vaccine efficacy.

2. Methods

Using TreeAge Pro 2009 (TreeAge Software, Williamstown, MA), we developed two decision analytic Monte Carlo computer simulation models:

* Corresponding author at: Public Health Computational and Operations Research Group (PHICOR), University of Pittsburgh, 200 Meyran Avenue, Suite 200, Pittsburgh, PA 15213, United States. Tel.: +1 412 246 6934; fax: +1 412 246 6954.

E-mail address: BYL1@pitt.edu (Bruce Y. Lee).

- **Initial Prevention Model:** depicting the decision whether to administer *C. difficile* vaccine to patients at-risk for CDI.
- **Recurrence Prevention Model:** depicting the decision whether to administer *C. difficile* vaccine to patients currently with CDI to prevent CDI recurrence.

The model assumed the societal, hospital, and third party payer perspectives and simulated the potential consequences of each decision.

Fig. 1a illustrates the Initial Prevention Model structure. Each patient had a risk of *C. difficile* colonization based on the local *C. difficile* prevalence. Figs. 1 and 2 show different variable names




Fig. 1. (a) Initial prevention main model structure. (b) Initial prevention mild disease outcomes sub-tree structure. (c) Initial prevention severe disease outcomes sub-tree structure.




Fig. 1. (Continued).

as the probabilities of moving down each branch. These variable names correspond to the variable names in the second column of Table 1. For example, the variable p_{Inf} represents the probability of infection; its complement $1 - p_{Inf}$ calculates the probability of no infection. The variable p_{Inf} draws from the distribution with the parameters indicated in Table 1. The median age of a patient was 71 years, the median age of patients discharged with a diagnosis of *C. difficile* from the 2007 National Inpatient Survey from the Healthcare Cost and Utilization Project [14]. Each colonized patient then entered into a *C. difficile* outcomes sub-tree. Colonized patients had probabilities of remaining asymptomatic carriers or progressing to CDI. Fig. 1b and c shows the CDI outcome models for mild and severe CDI, respectively. Both mild and severe CDI required antibiotic treatment, which had probabilities of being effective. Ineffective treatment allowed progression to more severe infections, requiring surgery and potentially leading to death. Patients successfully treated with antibiotics could either remain free of disease or suffer a CDI recurrence, i.e., reappearance of CDI within 3 months of successful treatment. Those who had a successfully treated first recurrence could then have a second recurrence. Patients who suffered two or more recurrences that were unsuccessfully treated had a probability of progressing to a severe disease state requiring surgery.

Fig. 2a depicts the main decision model for the Recurrence Prevention Model. For this model, the median patient age was also 71 years. Each patient began with successfully treated CDI and then had a probability of experiencing recurrent CDI. All recurrences had probabilities of progressing either to mild or severe disease. Fig. 2b represents the outcome model for mild CDI, while Fig. 2c represents

the outcome model for severe CDI, with both forms of CDI requiring antibiotic treatment. An effectively treated patient could then suffer a second recurrence. Ineffective treatments at any point in the model allowed progression to more serious CDI that required surgery and could result in death.

Treatment options depended on the disease severity, prior treatments, and number of recurrences. For mild disease, metronidazole was the first-line antibiotic treatment, and vancomycin was the second-line. For severe disease, the treatment of choice was vancomycin along with intravenous metronidazole prior to surgery. When patients suffered a recurrence, the first-line treatment was the same antibiotic that worked for the initial CDI episode (e.g., a patient who relapsed after being successfully treated with metronidazole then received metronidazole again). Patients suffering two or more recurrences received a tapered course of vancomycin. Additionally, patients with severe disease required peripheral intravenous line insertion as well as an abdominal computerized tomography.

Our model measures effectiveness in disability-adjusted life years (DALYs) prevented using the following formula:

$$DALY = YLL + YLD$$

where YLL = Years Lost to Life and YLD = Years Lost to Disability.

For each simulation run, we determined the incremental cost effectiveness ratio (ICER) of *C. difficile* vaccination as defined as:

$$= \frac{\text{Cost}_{\text{vaccination}} - \text{Cost}_{\text{no vaccination}}}{-(\text{DALYs}_{\text{vaccination}} - \text{DALYs}_{\text{no vaccination}})}$$




Fig. 2. (a) Recurrence prevention main model structure. (b) Recurrence prevention mild disease outcomes sub-tree structure. (c) Recurrence prevention severe disease outcomes sub-tree structure.

Vaccination was considered to be cost-effective if the ICER fell below three times the per capita gross domestic product (GDP) or \$80,412/DALY prevented for the United States, a frequently cited threshold for cost-effectiveness [15,16].

2.1. Data inputs

Table 1 lists the input parameters for the model, including variable names (featured in the figures), probabilities, costs, and utilities, as well as the distribution parameters for each variable. Probabilities assumed beta distributions, except for the efficacy of tapered vancomycin treatment (triangular distribution), as well as the probability of colonization and the probability of successful isolation, which were fixed values during each simulation. All costs were in 2009 U.S. dollars. A 3% discount rate adjusted all costs to 2009 dollars.

We used two separate approaches to determine the costs associated with CDI:

- **Health Care Resource Use:** A first approach involved identifying the procedure and hospitalization costs associated with different CDI conditions. Costs drew from triangular distributions, with several exceptions: costs of hospitalization, metronidazole [intravenous (IV) and oral (PO)], and surgery assumed gamma distributions, while the cost of in-hospital death was fixed at \$5000.

- **Opportunity Cost of Lost Bed-Days:** An alternative approach re-conducted our analyses using a method described by Graves to ascribe economic costs to hospital infections [17]. When CDI caused a patient to occupy a bed for a longer period of time, the hospital lost revenue because the bed could have been filled by another patient. The Graves method involved valuing the opportunity cost of a lost bed-day and then multiplying it by the extended hospital length-of-stay caused by the ensuing type of CDI.

Disability weights corresponding to diarrheal disease came from the World Health Organization's Global Burden of Disease [18]. CDI, CDI recurrences, and death each resulted in corresponding DALY increments (Table 1). The length of disease was 6 days, the median length of hospitalization for a 71-year-old patient with CDI.

2.2. Sensitivity analyses

Because *C. difficile* risk may differ significantly from hospital-to-hospital, sensitivity analyses systematically varied the risk of *C. difficile* from 0.1% to 90%. Additional sensitivity analyses ranged vaccine efficacy from 25% to 100%. Because one of our goals is to estimate the cost thresholds under which a vaccine would remain cost-effective, we started vaccine cost at \$25 for the Initial Prevention Model and \$100 for the Recurrence Prevention Model. We then systematically increased the

Table 1
Data inputs for model variables.

Description (units)	Variable name	Median	Upper limit (or SD ^a)	Lower limit	Source
Costs (US\$)					
Abdominal CT Scan		1,535.58	2057.68	1,013.48	[23]
Hospitalization		7,517.54	242.95 ^a		[14]
Metronidazole (IV)		107.86	10.28 ^a		[24]
Metronidazole (PO)		60.90	39.28 ^a		[24]
Peripheral intravenous line insertion		146.25	195.98	96.52	[25]
Surgery (colectomy)		15,995.10	5,412.71 ^a		[14]
Vancomycin		1,184.90	1587.77	782.03	[24]
Vancomycin (tapered)		2,221.70	2977.07	1,466.32	[24]
Utilities (DALYs)					
1st recurrence		-0.0029	-0.0019	-0.0039	[18]
2nd+ recurrence(s)		-0.0043	-0.0029	-0.0058	[18]
<i>C. difficile</i> infection		-0.0014	-0.0009	-0.0019	[18]
Mortality		-14.00	-9.24	-18.76	[18]
Probabilities (%)					
Given <i>C. difficile</i> colonization					
Developing <i>C. difficile</i> infection	pInf	26.15	25.69 ^a		[26–29]
Given <i>C. difficile</i> infection					
Mortality	pDeath	2.66	2.13 ^a		[14,30–32]
Recurrence	pRec	20.00	6.77 ^a		[33–35]
Severe disease	pSevDis	8.09	13.05 ^a		[30,36,37]
Mild disease		91.91 ^b	^b		[30,36,37]
Surgery (colectomy)	pSur	1.20	2.51 ^a		[19,30,34,38–42]
<i>C. difficile</i> treatment efficacies					
Metronidazole	pEffTxMet	90.41	9.28 ^a		[43–50]
Vancomycin	pEffTxVan	98.18	7.64 ^a		[45,46,48–53]
Vancomycin (tapered)	pEffTxTap	68.97	92.41	45.52	[54]

^a Standard deviation.^b Probability of mild disease is calculated as 1 – pSevDis.

cost of the vaccine until it was no longer cost-effective (consequently, sensitivity analyses ranged vaccine cost from \$25 to \$100 in the Initial Prevention Model and from \$100 to \$1600 in the Recurrence Prevention Model). Furthermore, probabilistic (Monte Carlo) sensitivity analyses simultaneously varied the values of each parameter throughout the ranges shown in Table 1. Another set of sensitivity analyses varied the probability of undergoing colectomy due to severe CDI from its baseline probability distribution listed in Table 1 down to 0.6% and 0.2%.

3. Results

3.1. Health care resource use approach

Each simulation run comprised of a cohort of 5000 patients, each travelling 5000 times through the model for a total of 25,000,000 simulated trials. Table 2 displays the results from the Initial Prevention Model when varying *C. difficile* risk, vaccine efficacy, and vaccine cost. Shaded cells correspond to situations where vaccination is not cost-effective. Vaccination was economically dominant

Table 2
Incremental cost-effectiveness ratio (US\$/DALY prevented) of vaccination for initial prevention of *Clostridium difficile* infection (CDI) using the health care resource use approach.

Vaccine efficacy (%)	<i>Clostridium difficile</i> risk							
	0.1%	1.0%	2.5%	5.0%	10.0%	15.0%	20.0%	25.0%
Cost of vaccination = \$25								
25	12,697,913	4,189,295	Dominant	Dominant	Dominant	Dominant	Dominant	Dominant
50	11,832,473	1,320,623	Dominant	Dominant	Dominant	Dominant	Dominant	Dominant
75	5,429,310	445,746	Dominant	Dominant	Dominant	Dominant	Dominant	Dominant
100	1,420,236	Dominant	Dominant	Dominant	Dominant	Dominant	Dominant	Dominant
Cost of vaccination = \$50								
25	28,084,233	4,329,877	2,176,586	727,421	Dominant	Dominant	Dominant	Dominant
50	26,917,206	4,074,365	522,459	Dominant	Dominant	Dominant	Dominant	Dominant
75	21,388,859	2,256,369	Dominant	Dominant	Dominant	Dominant	Dominant	Dominant
100	12,064,352	887,840	Dominant	Dominant	Dominant	Dominant	Dominant	Dominant
Cost of vaccination = \$100								
25	117,638,162	29,845,039	4,258,047	3,664,621	751,912	2,169	Dominant	Dominant
50	66,314,756	7,378,601	1,783,465	478,200	Dominant	Dominant	Dominant	Dominant
75	59,743,367	4,459,509	1,646,619	Dominant	Dominant	Dominant	Dominant	Dominant
100	41,956,115	3,483,069	539,666	Dominant	Dominant	Dominant	Dominant	Dominant

Note: Dominant = vaccination is the dominant strategy (i.e., less costly and more effective).

Table 3
Incremental cost-effectiveness ratio (US\$/DALY prevented) of vaccination for *Clostridium difficile* infection (CDI) recurrence prevention of using the health care resource use approach.

Vaccine efficacy (%)	Cost of vaccination				
	\$1600	\$800	\$400	\$200	\$100
25	354,064	92,691	Dominant	Dominant	Dominant
50	94,054	Dominant	Dominant	Dominant	Dominant
75	5,081	Dominant	Dominant	Dominant	Dominant
100	Dominant	Dominant	Dominant	Dominant	Dominant

Note: Dominant = vaccination is the dominant strategy (i.e., less costly and more effective).

(both less costly and more effective) over no vaccination when *C. difficile* risk was at least 5% at almost every vaccine efficacy and cost combination, except when vaccine efficacy dropped to 25% and vaccine cost was at least \$50 and when vaccine efficacy was 50% and cost was equal to \$100. A \$25 vaccine was dominant as long as *C. difficile* risk was at least 2.5%.

Table 3 shows results from the Recurrence Prevention Model at different vaccine efficacies and costs. Vaccination was cost-effective, and frequently economically dominant, in most situations. An \$800 vaccine was dominant as long as vaccine efficacy was at least 50%. Even at a cost of \$1600, a 75% efficacious vaccination was cost-effective.

Fig. 3 displays acceptability curves at different prevalence levels with vaccine efficacy equal to 75% and cost of vaccine equal to \$100 for the Initial Prevention Model. Each curve represents the proportion of patients per simulation for which vaccination was a more cost-effective strategy (optimal choice) over no vaccination at various willingness-to-pay (WTP) thresholds. For example, when *C. difficile* risk was 5%, vaccination was the optimal strategy for over 40% of patients, regardless of the WTP threshold. When risk was 10%, vaccination was the optimal choice for over 60% of patients at all WTP thresholds. Fig. 4 displays acceptability curves for the Recurrence Prevention Model at varying vaccine efficacy rates when the cost of vaccine was \$800. When vaccine efficacy was 50%, vaccination was the optimal choice for 68% of patients at

a WTP threshold of \$0. When vaccine efficacy was 75%, vaccination was the optimal selection for over 90% of patients, regardless of the WTP threshold. All results remained robust to (i.e., were not affected by) varying the probability of severe disease necessitating colectomy.

3.2. Opportunity cost of lost bed-days approach

Each simulation run comprised of a cohort of 5000 patients, each travelling 5000 times through the model for a total of 25,000,000 simulated trials. Table 4 presents the results for the Initial Prevention Model at varying *C. difficile* risk, vaccine efficacies, and vaccine costs. Vaccination was cost-effective when vaccine cost was \$25 and *C. difficile* risk was equal to or greater than 10%, except when efficacy was 25% and *C. difficile* risk was less than or equal to 15%.

Table 5 lists the cost-effectiveness of vaccination for the Recurrence Prevention Model. Vaccination was cost-effective at all vaccine efficacy and cost combinations, except when cost was equal to \$800 and efficacy was greater than or equal to 50% and when cost was equal to \$400 and efficacy was equal to 25%. Vaccination became dominant when the cost of vaccine was \$200 or less, except when efficacy dropped to 50% at vaccine cost \$200 and 25% at vaccine cost \$100. All results remained robust to varying the probability of colectomy.




Fig. 3. Acceptability curves at different *C. difficile* risk for vaccine efficacy of 75% and cost of vaccination of \$100 for initial prevention.




Fig. 4. Acceptability curves at different *C. difficile* vaccine efficacy for cost of vaccination of \$800 for recurrence prevention.

Table 4
Incremental cost-effectiveness ratio (US\$/DALY prevented) of vaccination for initial prevention of *Clostridium difficile* infection (CDI) using the opportunity cost of lost bed-days approach.

Vaccine efficacy (%)	<i>Clostridium difficile</i> risk							
	0.1%	1.0%	2.5%	5.0%	10.0%	15.0%	20.0%	25.0%
Cost of vaccination = \$25								
25	102,512,396	5,802,049	3,150,365	670,243	219,928	159,819	51,886	9,750
50	7,835,447	1,774,240	1,120,416	235,026	46,099	Dominant	Dominant	Dominant
75	9,242,325	1,135,269	437,496	125,266	Dominant	Dominant	Dominant	Dominant
100	13,588,967	1,114,979	300,389	56,679	Dominant	Dominant	Dominant	Dominant
Cost of vaccination = \$50								
25	355,495,778	9,495,689	4,775,304	1,901,144	697,507	419,099	312,448	189,174
50	62,561,269	3,928,690	2,619,269	674,142	260,932	130,529	54,358	5,540
75	38,053,933	3,606,097	1,274,169	448,297	134,118	29,308	Dominant	Dominant
100	31,053,420	2,377,616	755,625	271,070	46,872	Dominant	Dominant	Dominant
Cost of vaccination = \$100								
25	397,800,954	14,296,136	13,956,184	2,151,773	1,241,526	1,089,628	878,411	949,495
50	121,217,228	7,336,363	2,797,316	1,645,005	885,973	436,334	277,371	196,372
75	99,166,559	6,559,099	2,093,538	994,250	421,389	227,919	143,188	68,418
100	34,978,919	6,098,157	1,590,522	695,307	285,349	147,266	54,144	10,528

Note: Dominant = vaccination is the dominant strategy (i.e., less costly and more effective).

Table 5
Incremental cost-effectiveness ratio (US\$/DALY prevented) of vaccination for *Clostridium difficile* infection (CDI) recurrence prevention using the opportunity cost of lost bed-days approach.

Vaccine efficacy (%)	Cost of vaccination				
	\$800	\$400	\$200	\$100	\$50
25	243,994	107,576	42,704	9,247	Dominant
50	111,054	42,259	9,653	Dominant	Dominant
75	66,756	21,121	Dominant	Dominant	Dominant
100	43,500	8,919	Dominant	Dominant	Dominant

Note: Dominant = vaccination is the dominant strategy (i.e., less costly and more effective).

4. Discussion

C. difficile vaccination appears to be cost-effective for a wide range of *C. difficile* risks, vaccine efficacies, and vaccine costs. In fact, vaccination quickly becomes economically dominant as *C. difficile* risk and vaccine efficacy increase, suggesting that vaccination in some settings could actually save society, third party payers, and hospitals money while preventing morbidity and mortality. Economically dominant interventions are not common in health care, as many measures require some cost to prevent morbidity and mortality. Therefore, finding an intervention to be cost saving in addition to beneficial to health strongly supports its implementation. So, while the risk of *C. difficile* may vary significantly from health care facility-to-health care facility and patient-to-patient, vaccination may be favorable in many circumstances. This is compelling evidence for policymakers and researchers to further invest in the development of *C. difficile* vaccine.

If and when a *C. difficile* vaccine reaches the market, choosing an appropriate target population will be important. Even effective vaccines, such as the Lyme disease vaccine, have struggled when target populations were not selected carefully [13]. Our results suggest that preventing CDI recurrence may be good initial indication for the vaccine. This initial indication could support even higher vaccine prices, which may provide further motivation for manufacturers to bring the vaccine to market. As expected, broader use for the initial prevention of CDI may not support as high prices, but increased volume may compensate for lower prices. Our results also outlined possible effects of using various *C. difficile* risk thresholds if vaccination is to be restricted to higher-risk individuals.

The potential value of the vaccine stems from the heavy burden of CDI. Even mild disease such as diarrhea, abdominal pain, and nausea can add to costs and lengthen hospital stay. More severe conditions such as fever, severe shock or sepsis, and toxic mega-

colon can result in expensive procedures and may even lead to death. The biology of *C. difficile* makes it a difficult pathogen to control; *C. difficile* spores are resistant to heat, ethanol-based hand sanitizers, and quaternary ammonium disinfectants and can survive for months without proper disinfection [1]. In fact, *C. difficile* may be a growing problem. From 1993 to 2003, both the number of *C. difficile* cases and deaths more than doubled in the United States (cases went from 261 to 546 cases and deaths went from 20.3 to 50.2 per 100,000 discharged patients) [19]. Moreover, recent years have seen the emergence of a hypervirulent *C. difficile* strain [11].

Certainly, developing a functional *C. difficile* vaccine faces some technological challenges [20–22]. A parenteral or intravenous vaccine candidate may stimulate the production of circulating antibodies in the bloodstream but not adequately protect the gastrointestinal mucosa, where the pathogen inflicts most of its damage. Inducing complete mucosal protection (i.e., stimulating gut-associated lymphoid tissue) may require the stimulation of all immune system arms, including mucosal secretory IgA, functional serum IgG antibodies, and systemic and local cell-mediated immune responses. Direct local delivery of an adequate dose to the gastrointestinal mucosa may be possible but not necessarily easy. Achieving adequate protection may require an initial priming dose and then subsequent booster doses. Nonetheless, encouraging advances in mucosal immunization have occurred over the past decade. Flumist (a live attenuated influenza vaccine), the Sabin oral polio vaccine, Ty21a (for typhoid fever), CVD 103-HgR (for cholera), and RotaTeq (for rotavirus infection) are examples of licensed and effective mucosally administered vaccines.

Our intent was to be conservative and err on the side of underestimating the benefits of a *C. difficile* vaccine. Our model included only the more common CDI sequelae and, when choices were available, the less expensive procedures. It also excluded chronic disease exacerbations that CDI may induce (e.g., dehydration lead-

ing to diabetic ketoacidosis among diabetics) and relatively rare *C. difficile* complications. In addition, our model did not incorporate how vaccination could prevent *C. difficile* transmission or reduce the selection pressure for antibiotic-resistant bacteria (such as vancomycin-resistant *Staphylococcus aureus*) by minimizing the use of antibiotics to treat CDI. Moreover, combining vaccine with other infection control measures (e.g., hand hygiene and cohorting) could have compounding effects in controlling *C. difficile* spread.

4.1. Limitations

All computer models are simplifications of real life and cannot completely represent every possible *C. difficile* and CDI-associated factor, event, and outcome. Computer models also cannot fully represent the full spectrum of socio-demographic and clinical heterogeneity among hospital patients and hospitals. Additionally, as stated earlier, our model focused on more common clinical outcomes for which data were available and did not incorporate all of the potential benefits of vaccination. Finally, the data inputs for our model derived from different studies of varying quality.

4.2. Conclusions

Once developed, a *C. difficile* vaccine could be cost-effective over a wide range of *C. difficile* risk, vaccine costs, and vaccine efficacies. The vaccine could be particularly valuable for patients currently treated for CDI to prevent recurrent disease. Our study results support further investment into developing a *C. difficile* vaccine and suggest that vaccine efficacy targets do not necessarily have to be exceptionally high for the vaccine to have value. Our results also identified possible price points for the vaccine to assist manufacturers, third party payers, and other potential purchasers.

Acknowledgement

This study was supported by the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) grant 1U54GM088491-0109, the Pennsylvania Department of Health, and the Vaccine Modeling Initiative (VMI), funded by the Bill and Melinda Gates Foundation. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

References

- [1] Hull MW, Beck PL. *Clostridium difficile*-associated colitis. *Can Fam Physician* 2004;50(November):1536–40, 1543–5.
- [2] McFarland LV. Update on the changing epidemiology of *Clostridium difficile*-associated disease. *Nat Clin Pract Gastroenterol Hepatol* 2008;5(January (1)):40–8.
- [3] Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD. A DNA vaccine targeting the receptor-binding domain of *Clostridium difficile* toxin A. *Vaccine* 2009;27(June (27)):3598–604.
- [4] Brun P, Scarpa M, Grillo A, Palu G, Mengoli C, Zecconi A, et al. *Clostridium difficile* TxA314 and SLP-36kDa enhance the immune response toward a co-administered antigen. *J Med Microbiol* 2008;57(June (Pt 6)):725–31.
- [5] Ni Eidhin DB, O'Brien JB, McCabe MS, Athie-Morales V, Kelleher DP. Active immunization of hamsters against *Clostridium difficile* infection using surface-layer protein. *FEMS Immunol Med Microbiol* 2008;52(March (2)):207–18.
- [6] Pechine S, Janoir C, Boureau H, Gleizes A, Tsapis N, Hoys S, et al. Diminished intestinal colonization by *Clostridium difficile* and immune response in mice after mucosal immunization with surface proteins of *Clostridium difficile*. *Vaccine* 2007;25(May (20)):3946–54.
- [7] Ghose C, Kalsy A, Sheikh A, Rollenhagen J, John M, Young J, et al. Transcutaneous immunization with *Clostridium difficile* toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. *Infect Immun* 2007;75(June (6)):2826–32.
- [8] Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, et al. *Clostridium difficile* toxoid vaccine in recurrent *C. difficile*-associated diarrhea. *Gastroenterology* 2005;128(March (3)):764–70.
- [9] Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, et al. *Clostridium difficile* vaccine and serum immunoglobulin G antibody response to toxin A. *Infect Immun* 2003;71(March (3)):1608–10.
- [10] Kelly CP, LaMont JT. *Clostridium difficile* – more difficult than ever. *N Engl J Med* 2008;359(October (18)):1932–40.
- [11] Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. *Lancet* 2005;366(September (9491)):1079–84.
- [12] Kotloff KL, Wasserman SS, Losonsky GA, Thomas Jr W, Nichols R, Edelman R, et al. Safety and immunogenicity of increasing doses of a *Clostridium difficile* toxoid vaccine administered to healthy adults. *Infect Immun* 2001;69(February (2)):988–95.
- [13] Lee BY, Burke DS. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. *Vaccine* 2009;(September).
- [14] HCUP.net. Healthcare Cost and Utilization Project; 2007 [cited 2009 June 15]; Available from: <http://www.ahrq.gov/HCUPnet/>.
- [15] Sassi F. Calculating QALYs, comparing QALY and DALY calculations. *Health Policy Plan* 2006;21(September (5)):402–8.
- [16] Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. *Cost Eff Resour Alloc* 2003;1(December (1)):8.
- [17] Graves N, Halton K, Lairson D. Economics and preventing hospital-acquired infection: broadening the perspective. *Infect Control Hosp Epidemiol* 2007;28(February (2)):178–84.
- [18] Murray CJL, Lopez AD, Harvard School of Public Health, World Health Organization, World Bank. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank; Distributed by Harvard University Press; 1996.
- [19] Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of *Clostridium difficile* colitis in hospitalized patients in the United States. *Arch Surg* 2007;142(July (7)):624–31 [discussion 31].
- [20] Cross AS, Chen WH, Levine MM. A case for immunization against nosocomial infections. *J Leukoc Biol* 2008;83(March (3)):483–8.
- [21] Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. *Nat Med* 2005;11(April (Suppl. 4)):S45–53.
- [22] Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. *Nat Rev Immunol* 2006;6(February (2)):148–58.
- [23] East Ohio Regional Hospital. Patient Price Information List; 2006 [cited 2009 August 5]; Available from: <http://www.eastohioregionalhospital.com/pricelist.asp>.
- [24] Red Book 2009. Pharmacy's fundamental reference. 113 ed. New York: Thomson Reuters; 2009.
- [25] Schwengel DA, McGready J, Berenholtz SM, Kozlowski LJ, Nichols DG, Yaster M. Peripherally inserted central catheters: a randomized, controlled, prospective trial in pediatric surgical patients. *Anesth Analg* 2004;99(October (4)):1038–43 [table of contents].
- [26] Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of *Clostridium difficile* and serum levels of IgG antibody against toxin A. *N Engl J Med* 2000;342(February (6)):390–7.
- [27] Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN. Nosocomial *Clostridium difficile* colonisation and disease. *Lancet* 1990;336(July (8707)):97–100.
- [28] McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of *Clostridium difficile* infection. *N Engl J Med* 1989;320(January (4)):204–10.
- [29] Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by *Clostridium difficile* and decreased risk of subsequent diarrhoea. *Lancet* 1998;351(February (9103)):633–6.
- [30] Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, et al. Fulminant *Clostridium difficile*: an underappreciated and increasing cause of death and complications. *Ann Surg* 2002;235(March (3)):363–72.
- [31] Dubberke ER, Butler AM, Reske KA, Agniel D, Olsen MA, D'Angelo G, et al. Attributable outcomes of endemic *Clostridium difficile*-associated disease in nonsurgical patients. *Emerg Infect Dis* 2008;14(July (7)):1031–8.
- [32] Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M. Morbidity, mortality, and healthcare burden of nosocomial *Clostridium difficile*-associated diarrhea in Canadian hospitals. *Infect Control Hosp Epidemiol* 2002;23(March (3)):137–40.
- [33] Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of *Clostridium difficile*-associated diarrhea. *J Clin Microbiol* 2000;38(June (6)):2386–8.
- [34] Barbut F, Gariazzo B, Bonne L, Lalande V, Burghoffer B, Luiuz R, et al. Clinical features of *Clostridium difficile*-associated infections and molecular characterization of strains: results of a retrospective study, 2000–2004. *Infect Control Hosp Epidemiol* 2007;28(February (2)):131–9.
- [35] Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent *Clostridium difficile* diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. *Clin Infect Dis* 1997;24(March (3)):324–33.
- [36] Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. *Clostridium difficile*-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. *CMAJ* 2004;171(August (5)):466–72.
- [37] Rubin MS, Bodenstern LE, Kent KC. Severe *Clostridium difficile* colitis. *Dis Colon Rectum* 1995;38(April (4)):350–4.

- [38] Byrn JC, Maun DC, Gingold DS, Baril DT, Ozao JJ, Divino CM. Predictors of mortality after colectomy for fulminant *Clostridium difficile* colitis. *Arch Surg* 2008;143(February (2)):150–4 [discussion 5].
- [39] Hermsen JL, Dobrescu C, Kudsk KA. *Clostridium difficile* infection: a surgical disease in evolution. *J Gastrointest Surg* 2008;12(September (9)):1512–7.
- [40] Jobe BA, Grasley A, Deveney KE, Deveney CW, Sheppard BC. *Clostridium difficile* colitis: an increasing hospital-acquired illness. *Am J Surg* 1995;169(May (5)):480–3.
- [41] Koss K, Clark MA, Sanders DS, Morton D, Keighley MR, Goh J. The outcome of surgery in fulminant *Clostridium difficile* colitis. *Colorectal Dis* 2006;8(February (2)):149–54.
- [42] Morris AM, Jobe BA, Stoney M, Sheppard BC, Deveney CW, Deveney KE. *Clostridium difficile* colitis: an increasingly aggressive iatrogenic disease? *Arch Surg* 2002;137(October (10)):1096–100.
- [43] Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S. Outcome of metronidazole therapy for *Clostridium difficile* disease and correlation with a scoring system. *J Infect* 2007;55(December (6)):495–501.
- [44] Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, et al. Relatively poor outcome after treatment of *Clostridium difficile* colitis with metronidazole. *Clin Infect Dis* 2005;40(June (11)):1586–90.
- [45] Nair S, Yadav D, Corpuz M, Pitchumoni CS. *Clostridium difficile* colitis: factors influencing treatment failure and relapse – a prospective evaluation. *Am J Gastroenterol* 1998;93(October (10)):1873–6.
- [46] Olson MM, Shanholtzer CJ, Lee Jr JT, Gerding DN. Ten years of prospective *Clostridium difficile*-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. *Infect Control Hosp Epidemiol* 1994;15(June (6)):371–81.
- [47] Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, et al. Increasing risk of relapse after treatment of *Clostridium difficile* colitis in Quebec, Canada. *Clin Infect Dis* 2005;40(June (11)):1591–7.
- [48] Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, et al. Prospective randomised trial of metronidazole versus vancomycin for *Clostridium-difficile*-associated diarrhoea and colitis. *Lancet* 1983;2(November (8358)):1043–6.
- [49] Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of *Clostridium difficile*-associated diarrhea. *Clin Infect Dis* 1996;22(May (5)):813–8.
- [50] Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated diarrhea, stratified by disease severity. *Clin Infect Dis* 2007;45(August (3)):302–7.
- [51] de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and *Clostridium difficile*-associated diarrhea. *Antimicrob Agents Chemother* 1992;36(October (10)):2192–6.
- [52] Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for *Clostridium difficile*-induced diarrhea. A randomized double-blind trial. *Arch Intern Med* 1986;146(June (6)):1101–4.
- [53] Young GP, Ward PB, Bayley N, Gordon D, Higgins G, Trapani JA, et al. Antibiotic-associated colitis due to *Clostridium difficile*: double-blind comparison of vancomycin with bacitracin. *Gastroenterology* 1985;89(November (5)):1038–45.
- [54] McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent *Clostridium difficile* disease. *Am J Gastroenterol* 2002;97(July (7)):1769–75.